Testing blood markers in newly diagnosed multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study looks at “biomarkers,” or measurable signals in blood, in people with multiple myeloma who are being treated for the first time. It may help researchers understand the disease better and how it responds to treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma that is new (not treated before) and you need treatment
- You can give written consent after the study team explains it
- You are covered by a social security plan (or are a beneficiary of the same)
- You are not pregnant
- Your health outlook is at least about 6 months of expected follow-up time
- You are able to understand and freely agree to participate
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2/3 trial tests whether matching treatment choices to a patient’s myeloma risk pattern (using blood and scan results) improves outcomes. It is for people with newly diagnosed, untreated, symptomatic multiple myeloma who may also receive transplant-related treatment.
This study looks at “biomarkers” (measurable signs in your tumor and possibly blood) to understand your lymphoma’s genetic make-up. The goal is to see which markers may help doctors decide on treatment and timing.
This trial checks how certain blood “biomarkers” change after you receive donor stem cells to rebuild your blood and immune system. The goal is to learn whether these markers can better predict your immune recovery after transplant.
This trial studies myeloma (and closely related blood disorders) by using extra blood or bone marrow samples for lab research. It aims to help discover new ways to understand or treat myeloma.
This trial is testing a new type of blood test (called a liquid biopsy) to find multiple myeloma early by looking at tiny pieces of DNA in your blood. It is for people already diagnosed with multiple myeloma, smoldering multiple myeloma, or MGUS.
This study looks at stored blood (serum) samples to see whether a lab test called MALDI-TOF mass spectrometry can help analyze multiple myeloma proteins. If you have multiple myeloma (or are a healthy matched control), your existing lab samples may be used for testing.
Hear when a new Newly Diagnosed Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.